The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study | Haematologica
![MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/54d3f666-b588-436f-a7e4-79c1145c3415/gr1.jpg)
MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine
![A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11255-021-02860-4/MediaObjects/11255_2021_2860_Fig1_HTML.png)
A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink
![Randomized controlled trial of RTX vs ivMP for the treatment of active... | Download Scientific Diagram Randomized controlled trial of RTX vs ivMP for the treatment of active... | Download Scientific Diagram](https://www.researchgate.net/profile/Mario-Salvi-2/publication/269720986/figure/fig1/AS:299412795478018@1448396981047/Randomized-controlled-trial-of-RTX-vs-ivMP-for-the-treatment-of-active-moderate-to-severe.png)
Randomized controlled trial of RTX vs ivMP for the treatment of active... | Download Scientific Diagram
![E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders - ScienceDirect E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1090379820301999-gr2.jpg)
E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders - ScienceDirect
![Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12969-021-00627-w/MediaObjects/12969_2021_627_Fig1_HTML.png)
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text
![Clinical outcomes in dog and human after RTX treatment. Dogs injected... | Download Scientific Diagram Clinical outcomes in dog and human after RTX treatment. Dogs injected... | Download Scientific Diagram](https://www.researchgate.net/profile/Robert-Caudle/publication/322969929/figure/fig7/AS:591219021344772@1517969007916/Clinical-outcomes-in-dog-and-human-after-RTX-treatment-Dogs-injected-intrathecally-with.png)
Clinical outcomes in dog and human after RTX treatment. Dogs injected... | Download Scientific Diagram
![Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d23cf50e-d34f-4724-9243-071435a1ccd6/fx1.jpg)
Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to
![AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1132.3/F1.large.jpg)
AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases
![Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ff523df-8e05-4e4e-a6e6-6ab0db242181/gr1_lrg.jpg)
Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology
![Frontiers | A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications | Pediatrics Frontiers | A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications | Pediatrics](https://www.frontiersin.org/files/Articles/651323/fped-09-651323-HTML/image_m/fped-09-651323-g001.jpg)
Frontiers | A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications | Pediatrics
![Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12969-021-00627-w/MediaObjects/12969_2021_627_Fig5_HTML.png)
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text
![Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/07c04668-8914-4fb2-8503-90e11d1ea907/gr1_lrg.jpg)
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders
![Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12969-021-00627-w/MediaObjects/12969_2021_627_Fig6_HTML.png)
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text
![JCM | Free Full-Text | Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study | HTML JCM | Free Full-Text | Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study | HTML](https://www.mdpi.com/jcm/jcm-10-04941/article_deploy/html/images/jcm-10-04941-g001.png)